동물용 조제 시장 규모, 점유율, 동향 분석 : 제품별, 동물 유형별, 투여 경로별, 제형별, 지역별, 부문별 예측(2026-2033년)

Animal Drug Compounding Market Summary

The global animal drug compounding market size was estimated at USD 1.68 billion in 2025 and is projected to reach USD 3.25 billion by 2033, growing at a CAGR of 8.52% from 2026 to 2033. The market is advancing due to increasing demand for personalized veterinary therapies, shortages and discontinuation of commercial veterinary drugs and rising pet ownership and veterinary spending.

Rising complexity in veterinary care is driving demand for personalized drug formulations customized to diverse animal needs. The standardized medications often fail to provide precise dosing, suitable delivery routes, or acceptable palatability. Besides this, compounding enables veterinarians to adjust strength, formulation, excipients, and flavor, improving compliance and therapeutic outcomes. In addition, personalized therapies are particularly important for small mammals, geriatric animals, and chronic cases requiring long-term treatment. In addition, compounded drugs can be prepared as flavored suspensions, micro-dosed capsules, or transdermal gels to match species-specific requirements.

In addition, ongoing supply disruptions and discontinuation of veterinary drugs are increasing reliance on compounding to maintain continuity of care. The market withdrawals due to limited demand, manufacturing challenges, or regulatory changes often leave treatment gaps, particularly for niche species and specialized conditions. Besides this, veterinary compounding enables pharmacists to recreate discontinued medications or prepare therapeutic alternatives, ensuring uninterrupted access to essential therapies. This is especially critical for chronic, geriatric, and specialty treatments with limited commercial substitutes. In addition, growing supply chain volatility, raw material shortages, and shifting manufacturing priorities have made compounding an indispensable support system, particularly for rural veterinary practices and specialty clinics facing constrained drug availability.

Furthermore, rising global pet ownership, particularly among urban and middle-income households, is driving increased demand for veterinary care and personalized treatments. Besides this, pets are regarded as family members, encouraging higher spending on diagnostics, preventive care, and specialized therapies. Thus, compounded medications provide flexible, veterinarian-directed solutions when standard commercial products are unsuitable, especially for chronic diseases, pain management, and geriatric conditions. In addition, veterinary spending continues to grow across North America, Western Europe, and Asia Pacific, supported by rising disposable incomes and expanding pet insurance coverage. In the U.S., widespread pet ownership across multiple species further strengthens demand for customized, species-specific compounded formulations.

Global Animal Drug Compounding Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global animal drug compounding market report based on product, animal, route of administration, dosage form, and region:

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Oral
• Injectable
• Topical
• Other Routes
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Companion Animals
  • Dogs
  • Cats
  • Others
• Livestock Animals
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Anti-infective Agents
• Anti-inflammatory Agents
• Hormones & Substitutes
• CNS Agents
• Other Products
• Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
• Suspensions
• Solutions
• Capsules & Tablets
• Others
• Region Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Route of Administration
  • 1.2.2. Product
  • 1.2.3. Animal
  • 1.2.4. Dosage Form
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3 Volume-Pricing Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Personalized Veterinary Therapies
    • 3.2.1.2. Shortages And Discontinuation of Commercial Veterinary Drugs
    • 3.2.1.3. Rising Pet Ownership and Veterinary Spending
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of Standardized Regulatory Oversight
    • 3.2.2.2. High Cost and Limited Accessibility of Compounded Medications
  • 3.2.3. Market Opportunity Analysis
• 3.3. Pricing Model Analysis
• 3.4. User Perspective Analysis
• 3.5. Estimated Animal Population by Key Species & Key Countries, 2025
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis
• 3.7. Tariff Impact Analysis
  • 3.7.1. Sector Impact Analysis
  • 3.7.2. Geographical Impact Analysis
  • 3.7.3. Strategic Opportunities & Risk for the Animal Drug Compounding Sector
• 3.8. Illegally Marketed Veterinary Drug Compounding Analysis

Chapter 4. Animal Drug Compounding Market: By Route of Administration Estimates & Trend Analysis

• 4.1. Animal Drug Compounding Market, By Route of Administration: Segment Dashboard
• 4.2. Animal Drug Compounding Market, By Route of Administration Movement Analysis
• 4.3. Animal Drug Compounding Market Estimates & Forecasts, by Route of Administration, 2021 to 2033 (USD Million)
• 4.4. Oral
  • 4.4.1. Oral Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Injectable
  • 4.5.1. Injectable Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Topical
  • 4.6.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Other Routes
  • 4.7.1. Other Routes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Animal Drug Compounding Market: By Animal Estimates & Trend Analysis

• 5.1. Animal Drug Compounding Market, By Animal: Segment Dashboard
• 5.2. Animal Drug Compounding Market, By Animal Movement Analysis
• 5.3. Animal Drug Compounding Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 5.4. Companion Animals
  • 5.4.1. Companion Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Dogs
    • 5.4.2.1. Dogs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Cats
    • 5.4.3.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Livestock Animals
  • 5.5.1. Livestock Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Animal Drug Compounding Market: By Product Estimates & Trend Analysis

• 6.1. Animal Drug Compounding Market, By Product: Segment Dashboard
• 6.2. Animal Drug Compounding Market, By Product Movement Analysis
• 6.3. Animal Drug Compounding Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
• 6.4. Anti-infective Agents
  • 6.4.1. Anti-infective Agents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Anti-inflammatory Agents
  • 6.5.1. Anti-inflammatory Agents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Hormones & Substitutes
  • 6.6.1. Hormones & Substitutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. CNS Agents
  • 6.7.1. CNS Agents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Other Products
  • 6.8.1. Other Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Animal Drug Compounding Market: By Dosage Form Estimates & Trend Analysis

• 7.1. Animal Drug Compounding Market, By Dosage Form: Segment Dashboard
• 7.2. Animal Drug Compounding Market, By Dosage Form Movement Analysis
• 7.3. Animal Drug Compounding Market Estimates & Forecasts, by Dosage Form, 2021 to 2033 (USD Million)
• 7.4. Suspensions
  • 7.4.1. Suspensions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Solutions
  • 7.5.1. Solutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Capsules & Tablets
  • 7.6.1. Capsules & Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Animal Drug Compounding Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. WEDGEWOOD PHARMACY
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Vimian
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Pharmaca
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Akina Animal Health
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Triangle Compounding
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Davis Island Pharmacy and Compounding Lab
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Custom Med Compounding Pharmacy
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Central Compounding Center South
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Wellness Pharmacy of Cary
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Miller's Pharmacy
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives